Get started

Signalservice

Final fall? Bitcion Review #BTCAfter the last fall, you entered the zone of interest. Now, we are likely to go to the white box, from which we will see the final movement down and the subsequent impulse with the renewal of new tops or without dipping into the zone of 54-56k. I look at the market extremely positively. -Because everything is down right now - Altcoins -We've held the Bitcoin level. -In a few days, it's September. -Markets rise on fear. Best regards @Forexcryptowithjohn
Long
by Forexcryptowithjohn
Lingrid | NZDCAD short from STRONG resistance zoneThe market has reached a significant resistance level on the daily timeframe, specifically at the area where a sharp bearish move occurred two months ago. The price action is currently creating a broadening triangle pattern, which can indicate a loss of momentum and increased volatility. Considering these factors, I anticipate a pullback toward the support level, especially in light of the divergence observed in the price action. Additionally, the psychological level at 0.85000 adds weight to the potential for a retracement as we might look to take profits or reassess positions around this key area. My target is support level at 0.83700 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
1
EURUSD - correction from the Resistance zoneEURUSD is currently approaching a weekly resistance level that was last tested in December 2023. Since this resistance level previously triggered a bearish reversal, we could see a potential short-term pullback or choppy price action in this area. The price might attempt a false breakout above both the channel border and the resistance level, which could lead to a short-term correction in the market. The target is the support level around 1.10500
Short
by RTED_Investing
Lingrid | AUDCAD ranging MARKET. Potential SHORTFX:AUDCAD has been consolidating following a significant move, with price action fluctuating between established support and resistance levels. This consolidation phase has formed a slight descending channel. As the market approaches the highs from the previous week, we may witness a rebound from the channel's upper boundary and the upward trendline, suggesting a potential continuation of the current sideways trend. My target is support level at 0.91330 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
3
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
Lingrid | GOLD trend CONTINUATION patternThe price perfectly fulfills my last idea. It hit the target zone. OANDA:XAUUSD has formed a trend continuation pattern in the shape of an ascending triangle. This pattern indicates that buying pressure is increasing as the price continues to test the resistance zone, suggesting that a breakout could be imminent. I believe that if the price successfully breaks through this resistance level, it may continue to rally, potentially reaching the 2500 resistance zone. With high-impact news scheduled for today, there is a strong possibility that the market may be poised to push towards new all-time highs. Keep an eye on the market reactions to the news, as they may provide key insights into the strength of the breakout and overall market sentiment. My goal is resistance around 2555. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDLong
by Lingrid
3
Trading minute impulseOn the minute timeframe of XAUUSD at the moment we have the completion of the impulse formation. If the price continues to move in the direction of the impulse and the support zones do not allow it to overcome the base of the impulse, it may reach the targets 1 and 2. If the price fails to advance in the direction of the momentum and overcomes the support zone at the base of the momentum, it is very likely that the price will move sideways or against the direction of the momentum.
FXOPEN:XAUUSDLong
by syomking76418
Lingrid | EURUSD bullish TRADING OpportunityThe price has indeed fulfilled my previous target idea, reaching the anticipated level. After hitting that target, the market has pulled back, with bearish sentiment pushing the price towards the support zone. FX:EURUSD has seen a retracement from the weekly resistance zone. Currently, the market is bouncing off a support level that aligns with the 78% retracement of the previous bullish weekly price range. Given that the overall trend remains bullish, I believe the bounce from this support level increases the likelihood of the market moving higher from this area. Overall, I expect the price to climb, potentially retesting the recent resistance zone above if the price breaks through the trendline. My goal is resistance around 1.11300 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
5
Lingrid | BONKUSDT Range-Bound Market PRICE ACTIONBINANCE:BONKUSDT is currently consolidating, oscillating between resistance and support levels. Notably, it is fluctuating around the psychological level of 0.000020, which indicates that there is accumulation occurring at this level. Overall, the market has reached the April high, and on the weekly timeframe, it has formed an inside bar pattern. This could signal the potential beginning of a bull run if the price closes above this pattern. I expect the market to continue oscillating within the consolidation zone until we see a clear breakout. Any movement beyond the established resistance or support levels will provide further insights into the market's direction. My target is resistance zone aroud 0.0000222 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
2
Lingrid | EURUSD weekly RESISTANCE zone. ShortFX:EURUSD has experienced a short-term pullback and then proceeded to make higher highs and higher closes. The market has broken through the previous day's high while moving upward to test the psychological level at 1.12000. This level is significant as it's the same zone where the market declined sharply last year in July. Currently, the price has reached the upper border of the channel, forming a 1-2-3 extension and exhibiting a bearish divergence. Given these factors, I anticipate a potential fake breakout at the channel border, which aligns with the highs of 2023. Therefore, I expect a pullback from this channel border, coinciding with weekly resistance levels. My target is the support level around 1.10820 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
12
Lingrid | GBPNZD consolidation before EXTENSION. ShortThe price perfectly fulfills my last idea. It hit the target. FX:GBPNZD is currently consolidating between resistance and support levels. On the daily timeframe, the price has experienced a bearish movement, and for the past two weeks, the market has repeatedly tested the same support level. I believe that a break below this support is likely, which would lead to an impulsive bearish move. At this stage, I anticipate a potential downward movement by breaking through last week's low. If the price successfully breaks and closes below the support level, I expect the further bearish trend to continue. My target is the support level around 2.10050 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
5
Lingrid | GOLD Weekly Technical AnalysisThe surge in OANDA:XAUUSD price following Jerome Powell's speech underscores the market's reaction to potential shifts in monetary policy. His indications of a likely interest rate cut, possibly occurring in September, have prompted a weakening of the U.S. dollar and a decline in Treasury yields, further enhancing gold's appeal as a safe-haven asset. As a result, the weekly candle closed as a green doji, reflecting both investor sentiment and anticipation of shifts in economic conditions. The market bounced off the swap zone and closed above the psychological level; however, there was not enough momentum to retest the previous higher high, which also represents an all-time high (ATH). This indicates that the market may now consolidate around the 2500 level or below the previous resistance zone to accumulate liquidity for a potential move to higher levels. On the daily timeframe, price action remains within the range of the previous day, suggesting the possibility of forming a triangle trend continuation pattern. It seems that there will be fewer high-impact news events next week, which may result in less momentum in the market. Nevertheless, we must remain cautious of the uncertainty in the market and be prepared to respond accordingly. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDLong
by Lingrid
19
XAUUSD 4HR Analysis UpdateGold took a tumble mid week down to $2,495 which saw it respect the same dynamic support level and 50 ema for the second time in the last week as we saw last thursday, as price is now respecting this key level and ranging between this and the all time high with gold teasing a break above the resistance with the bull trend still intact in a continuation play its likely we will soon see new all time highs unless gold breaks the key support, closes below such and the floating dynamic ema whilst invalidating the market structure. Going forwards I can see price still ranging between the lower $2,500's with perhaps a lower high in the smaller time frames created around $2,506 as a short term target before aiming for longer term target of $2,550 and so on.
BLACKBULL:XAUUSDLong
by OfficialKieranTrewick
Lingrid | ETHUSDT building Block of ACCUMUALTION Befor ExpansionBINANCE:ETHUSDT is clearly in the accumulation phase, sitting just below the psychological level of 3000. Recently, the price hit a support level that was also tested back in February and subsequently bounced off it. Over the past three weeks, we've observed mostly sideways movement. When examining the weekly timeframe, it's evident that the market formed a long-tailed bar, indicating a liquidity grab below the February low. This suggests that there was strong buying interest after the dip. Given that the market has retested the recent low area and rebounded, I believe we can expect a gradual upward movement from here. My target is resistance zone around 2950. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
3
Nvidia Stock Soars On Blowout GuidanceSoaring demand for the chips needed to train the latest wave of generative artificial intelligence systems such as ChatGPT led Nvidia to issue a revenue forecast far ahead of Wall Street expectations, prompting a surge in its stock price in after market trading. The US chipmaker on Wednesday said it expected sales to reach 11bn dollar in the three months to the end of July, more than 50 per cent ahead of the 7.2bn dollar analysts had been expecting and confirming its position as the biggest short-term beneficiary of the AI race that has broken out in the technology industry. The forecast fuelled a 27 per cent leap in Nvidia’s shares, which had already more than doubled since the start of the year, and lifted its stock market value to a record 960 bn dollar. Jensen Huang, chief executive, said the company was “significantly increasing our supply to meet surging demand” for its entire family of data centre chips, including the H100, a product launched this year that was designed to handle the demands of so-called large language models such as OpenAI’s GPT4. The race in the tech industry to develop larger AI models has led some customers to worry privately about a shortage of H100 chips, which only went on sale earlier this year. However, Nvidia’s $4.28bn in sales to data centre customers in its latest quarter topped even the most optimistic analysts’ forecasts, and the company said there had been strong sales of both the H100 and its A100 chips, based on its previous chip architecture. Nvidia’s forecast noted a potential doubling of sales to data centre customers in three months, even though data centre sales were running at an annualised rate of $17bn in the opening quarter of this year. Growth is coming from customers across the board, Kress said, with consumer internet companies, cloud computing providers and enterprise customers all rushing to apply the generative AI to their businesses. The bullish forecast came as Nvidia reported revenue and earnings in its latest quarter, to the end of April, had also topped forecasts, thanks to a jump in sales to data centre customers as demand for AI took off. Revenue reached $7.19bn, up 19 per cent from the preceding three months but down 13 per cent from the year before, as sales of chips for gaming systems dropped. Earnings per share rose 22 per cent from a year before to 82 cents, or $1.09 on the pro forma basis Wall Street judges the company. The consensus view on Wall Street had been for revenue of $6.52bn and pro forma earnings of 92 cents a share. now let's delve into the numbers. Nvidia's different business units did not all perform equally well during the quarter - which can be expected, of course. Nvidia's data center business grossed revenues of $4.3 billion during the first quarter, which represents a new record high. Data center demand is not very cyclical, and companies kept investing in new equipment despite a potential recession being on the horizon. This can be explained by the fact that data centers are mission critical for many companies, so they don't really have a lot of choice when it comes to allocating capital to this space. Strong data center sales also have been seen in the results of other chip companies such as Advanced Micro Devices (AMD). Both Nvidia and AMD also were able to benefit from the weak performance of their competitor Intel (INTC), as Intel has been losing market share in the data center space in recent quarters due to self-inflicted problems and an unconvincing product line-up. Nvidia is a major graphic chip or GPU player and is thus heavily impacted by the performance of related end markets. This includes both cryptocurrency mining and gaming. While some cryptocurrencies can't be mined with GPUs economically, such as Bitcoin, others, such as Ethereum, can be mined with GPUs. Ethereum moved from a proof-of-work model to a proof-of-stake model in the fall of 2022, but some miners still use GPUs for Ethereum mining. Not surprisingly, Nvidia's sales to this end market depend on the price for cryptocurrencies - when cryptocurrencies are expensive, miners are more eager to acquire additional GPUs and they may also be willing to pay high prices for them. During times when cryptocurrencies are less expensive, mining is less profitable, and GPU demand from cryptocurrency miners wanes. This has had an impact on Nvidia's sales in the past and likely played a role in Nvidia's Q1 sales as well. GPU sales have been under pressure in recent quarters due to lower demand by gamers as well. Many that like to play video games upgraded their hardware during the lockdown phase of the pandemic when staying at home meant that consumers had more time for video games. With many gamers having relatively new equipment, demand has declined in the recent past. At the same time, inflation pressures consumers' ability to spend on discretionary goods. On top of that, some consumers prefer to spend their money on experiences over things now as there are no lockdowns or travel restrictions in place any longer. All in all, this has resulted in a difficult macro environment for Nvidia's gaming business. Combined, the headwinds for the gaming market and the cryptocurrency market explain why Nvidia's sales and profits kept declining during the most recent quarter, relative to the results the company was able to generate one year earlier. The strong performance in the data center space was not enough to offset the headwinds Nvidia experienced in other areas. I personally going to take huge profit right now and wait for 250 $ levels
NASDAQ:NVDA
by moonypto
5
Lingrid | AVAXUSDT key Support Signals Potential ReversalThe price perfectly fulfilled my previous idea. It hit the target level. As you've observed, BINANCE:AVAXUSDT has reached the resistance level and subsequently pulled back with bearish momentum. The price is now approaching the channel border, which has served as support multiple times in the past. This sets the stage for a potential reversal. The presence of the round number 23.00 below adds another layer of significance to this support area. The 50% Fibonacci retracement level is also an important factor to consider, as it can often act as a endpoint for corrections in a prevailing trend. Given these conditions, I anticipate potential rejection patterns at this support zone, such as a long-tailed bar or an engulfing candle. These price action signals would indicate a strong buyer interest at this level and could reinforce a bullish outlook if confirmed. My target is resistance around 26.55 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
1